Founded in 2017, Naveris is a privately held biotechnology company with facilities in Massachusetts and North Carolina. The company's mission is to improve outcomes for the millions of people at risk of developing viral cancers through novel molecular diagnostics that enable earlier cancer detection. Naveris' clinical laboratory is certified for high complexity testing under CLIA, and is accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/19/22 | $51,000,000 | Series A |
BrightEdge Fund Gurnet Point Capital  TechU Ventures | undisclosed |
